PTGS2 and head and neck cancer: This can be confirmed by the findings that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) can reduce risk of gastrointestinal cancer and the growth of head and neck cancer [74–76] through blockading COX-1 and COX-2 activities, which subsequently suppresses prostaglandin, including PGE2, biosynthesis.